SCHEMBL7915892

SCHEMBL7915892

O=C(O)C1CCCN1C(=O)CCCCC1CCSS1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 2/20 0.57
▸ KMT2A Q03164 2/20 0.57
▸ TARDBP Q13148 2/20 0.57
▸ CYP2C9 P11712 1/20 0.57
▸ MEN1 O00255 1/20 0.57
▸ NR1I2 O75469 1/20 0.57
▸ ALDH1A1 P00352 1/20 0.57
▸ LMNA P02545 1/20 0.57
▸ POLB P06746 1/20 0.57
▸ THRB P10828 1/20 0.57
▸ TSHR P16473 1/20 0.57
▸ ACHE P22303 1/20 0.57
▸ APEX1 P27695 1/20 0.57
▸ RECQL P46063 1/20 0.57
▸ BLM P54132 1/20 0.57
▸ PMP22 Q01453 1/20 0.57
▸ TDP1 Q9NUW8 1/20 0.57
▸ SAE1 Q9UBE0 1/20 0.57
▸ UBA2 Q9UBT2 1/20 0.57
▸ L3MBTL1 Q9Y468 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10067900 1.00 HSD17B10 (0.57) HSD17B10KMT2ATARDBPCYP2C9MEN1
SCHEMBL7919690 0.96 HSD17B10 (0.56) HSD17B10KMT2ATARDBPCYP2C9MEN1
SCHEMBL12227662 0.88 HSD17B10 (0.51) HSD17B10KMT2ATARDBPCYP2C9MEN1
SCHEMBL7912695 0.85 SIGMAR1 (0.49) HSD17B10KMT2ATARDBPCYP2C9MEN1
SCHEMBL12227665 0.84 SIGMAR1 (0.53) HSD17B10KMT2ATARDBPCYP2C9MEN1
SCHEMBL7910566 0.82 SIGMAR1 (0.51) HSD17B10KMT2ATARDBPCYP2C9MEN1
Miridesap SCHEMBL1685022 0.82 ACE (0.68) ACE
Miridesap SCHEMBL6788714 0.82 ACE (0.68) ACE
Miridesap SCHEMBL1537496 0.82 ACE (0.68) ACE
Miridesap SCHEMBL1537499 0.82 ACE (0.68) ACE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110257130-A1 Compositions and Methods for Treatment of Renin-Angiotensin Aldosterone System (RAAS)- Related Disorders CARMEL BIOSCIENCES, INC. 2011-10-20 — — US disclosed
US-20110257130-A1 Compositions and Methods for Treatment of Renin-Angiotensin Aldosterone System (RAAS)- Related Disorders CARMEL BIOSCIENCES, INC. 2011-10-20 — — US disclosed
WO-2010045575-A2 COMPOSITIONS AND METHODS FOR TREATMENT OF RENIN-ANGIOTENSIN ALDOSTERONE SYSTEM (RAAS)-RELATED DISORDERS INVASC THERAPEUTICS, INC. (US) 2010-04-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257130-A1 Compositions and Methods for Treatment of Renin-Angiotensin Aldosterone System (RAAS)- Related Disorders REN, ACE, AGT HSD17B10 292/4885KMT2A 3405/4885TARDBP 4632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback